Report Overview
The Global Pharma Hub and Patient Access Support Service Market size is expected to be worth around US$ 10.0 Billion by 2035 from US$ 3.6 Billion in 2025, growing at a CAGR of 10.8% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 45.6% share with a revenue of US$ 1.7 Billion.
Increasing complexity of specialty drug access and regulatory requirements drives the Pharma Hub and Patient Access Support Service market as pharmaceutical manufacturers require integrated platforms to ensure timely patient enrollment, reimbursement navigation, and ongoing adherence.
Manufacturers increasingly partner with hub service providers to manage prior authorization processes for high-cost biologics and gene therapies, streamlining submissions and appeals to payers for conditions such as multiple sclerosis, rheumatoid arthritis, and rare genetic disorders.
